Cyclacel Pharmaceuticals Inc Investor Relations Material
Latest events
Q4 2023
Cyclacel Pharmaceuticals Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Cyclacel Pharmaceuticals Inc
Access all reports
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc., is developing fadraciclib, a cyclin dependent kinase Inhibitors (CDK) program that has completed Phase 2b clinical trials for the treatment of solid tumors. The Company's development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease as well as its Phase 1/2 IST for the treatment of advanced rheumatoid arthritis.
Key slides for Cyclacel Pharmaceuticals Inc
Investor Presentation
Cyclacel Pharmaceuticals Inc
Investor Presentation
Cyclacel Pharmaceuticals Inc
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States